Helix BioPharma Strengthens Leadership with Strategic Executive Appointments

Helix BioPharma, a clinical-stage oncology company, has reinforced its leadership team with two strategic executive appointments aimed at driving organizational growth and advancing its mission to develop innovative cancer treatments.

Veronika Kandziora, named Chief Operating Officer, brings over two decades of cross-sector leadership experience in biopharma, finance, and consulting. Her extensive background includes serving as Corporate Secretary for Helix from 2017-2019 and working as a strategic consultant, providing her with deep institutional knowledge and a comprehensive understanding of the company's objectives.

Complementing Kandziora's appointment, Dr. Jessica Kourniaktis joins as Director of Communications, bringing a decade of experience in life sciences communications. Her unique background combines academic expertise with strategic storytelling, having previously advised clients in oncology and served in executive roles at multiple biopharma startups.

CEO Thomas Mehrling emphasized the strategic importance of these appointments, noting that Kandziora and Kourniaktis will be critical in helping the company navigate its next developmental phase. Their combined expertise is expected to enhance Helix's operational efficiency and communication strategies.

Kandziora highlighted the company's pivotal stage of development, focusing on creating a strong, agile operational foundation that can support innovative cancer treatment development. Meanwhile, Kourniaktis aims to amplify the company's narrative and increase public understanding of their groundbreaking work.

These appointments come at a crucial time for Helix BioPharma, which is developing innovative oncology treatments, including its lead candidate L-DOS47, an antibody-enzyme conjugate targeting CEACAM6-expressing solid tumors. The new leadership is expected to accelerate the company's mission of developing treatments for challenging cancer types.